IPO Action Brief: SCTX prices at $15, but retail access is still unverified
Scribe Therapeutics priced its upsized SCTX IPO at $15 and is expected to trade today, but no mainstream U.S. retail allocation is verified; Zhongji Innolight remains open in Hong Kong through July 27.
Today's spotlight: SCTX reaches the market, but primary access is still unverified
Status: Expected to begin trading Friday, July 24, 2026
Ticker: SCTX
Final price: $15.00
Deal size: 8.58 million shares; $128.7 million gross proceeds
Minimum buy-in: Not applicable to a verified public retail allocation
Broker access: No confirmed allocation path through Robinhood, Fidelity, Schwab, E*TRADE, or Webull
Scribe Therapeutics is a clinical-stage biotech developing in vivo CRISPR medicines, with STX-1150 as its first clinical program for lowering LDL cholesterol by repressing PCSK9. The company priced its IPO at the top of the previous $13-$15 range and increased the offering from 7.15 million shares in its amended filing to 8.58 million shares in the final pricing release. The expected gross proceeds are $128.7 million before expenses. 1 2
The headline investment angle is a possible one-time or durable approach to a chronic cholesterol problem. The risk is much nearer-term: STX-1150 is only in its first-in-human study, planned for up to 64 adults, with initial safety, tolerability, and LDL-C data expected in the first half of 2027. The SEC filing also says the company has substantial doubt about its ability to continue as a going concern and will need significant additional capital, even after the offering and related private placement. 2
Scribe also disclosed a concurrent Sanofi private placement of 500,000 shares at $15, or $7.5 million, expected to close July 27 if the IPO closes. That is a strategic support signal. It is not a retail oversubscription figure, and it does not establish that a mainstream broker is accepting allocation orders. 1
Actionable now
No U.S. retail IPO allocation window met the verification standard this morning. SCTX has a final price and an expected listing date, but the public records reviewed do not show a confirmed broker order page with a deadline, minimum buy-in, and access path. Treat it as a listing-day watch rather than an open subscription. Ordinary stock trading after the debut is a separate question from receiving IPO shares. 1 3
| Offer | Price range or terms | Minimum buy-in | Deadline | Verified brokers |
|---|---|---|---|---|
| None verified | Not applicable | Not applicable | No verified open U.S. window | None publicly verified |
Market pulse
- Top-of-range pricing came with a larger deal. SCTX priced at $15 and sold 8.58 million shares, versus the 7.15 million shares and $13-$15 range in the amended filing. That shows stronger final deal execution than the last public terms, but it still does not tell us how much retail demand was in the book. 1 2
- Strategic participation is disclosed; social demand is not. Sanofi is buying $7.5 million of stock in the concurrent placement. Eli Lilly has described a non-binding intention that could bring its combined ownership to as much as 10.9%. No public candidate-specific oversubscription multiple or reliable social-buzz metric was verified. 2
- The Friday calendar is busy but thin on terms. Yahoo lists seven expected July 24 entries, including SCTX, Tarsier Pharma, American Battery Materials, and several units or warrants. For the other entries, the calendar shows no price or share count, so they are listing watches rather than confirmed retail allocations. 3
HK desk
Zhongji Innolight (03308) is the only Hong Kong public subscription I could verify as open today. Phillip lists an offer price of HK$1,010, public subscription closing on July 27, and a July 30 listing. ET Net lists a 50-share board lot, which puts the nominal minimum at HK$50,500 before fees. 4 5
That entry cost is high for a small account. The readable terms came from Phillip and ET Net, both supplemental public sources; the matching HKEX page did not expose readable subscription terms in this run. Check the exchange filing or your eligible international broker before submitting an application. 4 5
| HK public offer | Offer price | Board lot | Nominal minimum before fees | Deadline | Listing |
|---|---|---|---|---|---|
| Zhongji Innolight (03308) | HK$1,010 | 50 shares | HK$50,500 | July 27 | July 30 |
On the radar
| Company | Next event | Terms | Why it matters |
|---|---|---|---|
| Ionic Digital (IOND) | Expected Nasdaq direct listing, July 28 | Reference price $53; no primary capital raise | It is a direct listing of existing shareholder shares, so the event is a trading watch rather than a new-share subscription. 6 |
| Jersey Mike's (JMKE) | Expected NYSE trade, July 30 | $21-$25; 43.5 million shares; about $1.0 billion at the midpoint | A familiar franchised sandwich chain with about 3,300 U.S. locations gives retail investors a recognizable consumer test, but no public allocation path is confirmed here. 7 |
| Reformation (REF) | Expected NYSE trade, July 30 | $15-$17; 14.1 million shares; about $225 million | The DTC womenswear brand is a smaller consumer deal with 70 stores and a strong brand-led retail angle, still awaiting final pricing. 8 |
Friday, July 24, 2026 is a regular U.S. trading day under the NYSE calendar. The practical read is narrow: SCTX has moved from an unpriced prospectus watch to a priced listing event, Zhongji has the only verified live public deadline in this brief, and no mainstream U.S. IPO allocation is confirmed. This is market information, not investment advice. 9
参考ソース
- 1Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering
- 2Scribe Therapeutics amended S-1/A
- 3Yahoo Finance IPO calendar for July 24, 2026
- 4Phillip Securities IPO Information
- 5ET Net new listings memorandum
- 6Ionic Digital Nasdaq direct listing notice
- 7Jersey Mike's IPO profile
- 8Reformation IPO profile
- 9NYSE holidays and trading hours
関連コンテンツ
- ログインするとコメントできます。